Asensus Surgical has received 510(k) clearance from the FDA for an expanded indication to treat adult and pediatric Urology patients with the Senhance Surgical System. While the Senhance System has been utilized for Urology procedures outside the U.S. for several years, this expanded indication will open the door to this specialty to leverage the advantages of the Senhance System in the U.S. patient population.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASXC:
- Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program
- Asensus Surgical’s Senhance Surgery System selected by Austrian hospital
- Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program
- Asensus Surgical: St. Marianna University to lease Senhance Surgical System
- KARL STORZ to acquire Asensus for 35c per share in cash